Phio Pharmaceuticals Corp (PHIO)

[Inoviorulez]

The collaborations with MirImmune ( I guess some people question this one since its with Alexey Wolfson as CSO) and PCI Biotech are good collaborations. Both these companies want to use the sd-rxRNA platform to deliver siRNA molecules to protein targets.

1.MirIMMUNe wants to target cancer proteins with immunotherapy checkpoint inhibitors
2.PCI biotech wants to use siRNA molecules against cancer cells combining their gene together with the sd-rxRNA delivery platform.

Hypertrophic scar study 1301 performed better than placebo at the 3 month time point. Company learned from 1301 and is incorporating more doses and spread out dosing through proliferation phase in the second hypertrophic scar study 1402.

Keloid trial was check out by panel of dermatologists who determined RXi-109 performed better than placebo at the 3 month time point. Panel unanimously recommended that Rxi being another keloid trial (like the 2nd hypertrophic scar trial) to add more doses and higher doses to improve efficacy even more.

Samcyprone will start soon with phase 2b trials by the end of 2015 with collaborations targeting warts, alopecia aerata, and metastatic melanoma (skin cancer)

Retinal scarring IND will be filed in mid 2015 (a few weeks months from now) and will first target the scarring of macular degeneration. Company will then begin phase 1 trial

Company should announce soon those new targets they announced collagenese/Tyrosinsae.

Did I miss anything? The company is on track. All is in order, the only short term problem is cash and many are wondering why the company hasn't diluted by now? Maybe they have a deal lined up who knows? All I know is that I like what the CEO has done thus far and I trust him to build value for the future of Rxi Pharmaceuticals.